Related Experiment Video

Updated: May 17, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

Axitinib, a new therapeutic option in renal cell carcinoma

E R Kessler1, D W Bowles, T W Flaig

  • 1University of Colorado School of Medicine, Division of Medical Oncology, Denver, Colorado 80045, USA.

Drugs of Today (Barcelona, Spain : 1998)
|October 31, 2012
PubMed

Insights

Axitinib, a targeted therapy, is a new treatment for metastatic kidney cancer. It inhibits key receptors involved in cancer growth, offering a new option for patients.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Kidney cancer development is linked to VHL gene mutations.
  • Targeting angiogenesis pathways is a key strategy in renal cell carcinoma treatment.
  • Axitinib is a novel small-molecule inhibitor.

Purpose of the Study:

  • To review the preclinical pharmacology of Axitinib.
  • To summarize the pharmacokinetics and clinical activity of Axitinib.
  • To define the role of Axitinib in current renal cell carcinoma treatment.

Main Methods:

  • Literature review of preclinical studies.
  • Analysis of pharmacokinetic data.
  • Evaluation of clinical trial results for Axitinib in metastatic renal cell carcinoma.

Main Results:

  • Axitinib targets specific tyrosine kinase receptors, including VEGFR.
  • Preclinical data support its anti-angiogenic and anti-tumor effects.
  • Clinical trials demonstrate significant activity in metastatic renal cell carcinoma.

Conclusions:

  • Axitinib is an effective targeted therapy for metastatic renal cell carcinoma.
  • Its mechanism of action involves inhibiting key growth factor receptors.
  • Axitinib represents a significant advancement in the treatment landscape for kidney cancer.

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.